Jacobio Pharma
IPO加科思药业|以患者受益为导向
Public · Beijing, China · $55.0M raised
- Headquarters
- Beijing
- Employees
- 51–200
- Business Model
- B2B
- Website
- jacobiopharma.com
- Total Funding
- $55.0M
- Last Round
- $55.0M Series CAug 2018
- Rounds
- 2
- Type
- Public
About
China-based oncology drug discovery company developing induced allosteric inhibitors targeting the KRAS pathway and STING pathway.
Summary
Jacobio Pharma is an Oncology company based in Beijing, China. It has raised $55.0M in total across 2 rounds, most recently a $55.0M Series C round in Aug 2018. Investors include Qiming VP, Hillhouse Capital and Lilly Asia Ventures.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Jan 2020
Sign up to see all 3 rounds
Series B through IPO — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
AI-native drug discovery company, now operating as Numerion Labs, that uses machine learning to e...
Numab designs and develops a new class of powerful therapeutics for the treatment of severe disea...
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/jacobio-pharma"><img src="https://indexed.vc/api/badge/company/jacobio-pharma" alt="Jacobio Pharma on Indexed.vc" width="260" height="76" /></a>